2025 DIGITAL CMC SUMMIT / ON-DEMAND SESSION
CMC Data: A New Frontier for the BioPharma Gold Rush
In this year’s Lightning Talks, get rapid-fire insights on AI, automation, and the digital workflows redefining CMC efficiency.
Session highlights & insights
See why the success of industry AI initiatives depends of a foundation of strong knowledge management.
Discover how tech transfer is being transformed by seamless integration of data, digital tools, and automation.
Get a first look at cutting-edge solutions for data strategy, governance, and workflow orchestration.
Discover how GenAI is already revolutionizing regulatory documentation processes.
SUMMARY
Welcome to CMC's AI revolution: Faster tech transfers, smarter decision-making & much more.
The Lightning Talks at the 2025 Digital CMC Summit took attendees straight to the cutting edge of AI, data-driven process development, and knowledge management in technical development. Featuring experts from ZS Associates, Thermo Fisher, and QbDVision, this session explored how AI-powered knowledge models, digital tech transfer, and predictive analytics are accelerating drug development and regulatory workflows.
From leveraging transfer learning to streamline manufacturing scale-up to building multi-agent AI frameworks for a range of CMC use cases, these talks provided a glimpse into the next era of drug development innovation. Watch this session to learn:
– Why robustly structured knowledge management are table stakes for AI in CMC.
– How digital-first approaches to tech transfer are already slashing time and costs.
– How predictive modeling is helping drug developers streamline experiment design and data analysis.
– What the latest FDA guidance on AI means for tomorrow’s regulatory submissions.
Sign up below to unlock all the insights!
Stream these exclusive insights from the 2025 Digital CMC Summit
Sign up to watch full sessions captured live at the 2025 Digital CMC Summit — including in-depth presentations, Q&A, and moderated deep-dives into our industry’s digital future.